Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-26T20:11:41.029Z Has data issue: false hasContentIssue false
  • English
  • Français

Trastorno psicótico inducido por interferón-a en un paciente con hepatitis C crónica

Published online by Cambridge University Press:  12 May 2020

V. Bozikas ,
P. Petrikis ,
A. Balla  and
A. Karavatos
V. Bozikas
Affiliation:
Clínica Psiquiátrica “A” de la Universidad Aristóteles de Tesa Iónica, Hospital Psiquiátrico de Tesa Iónica, Tesalónica, Grecia
P. Petrikis
Affiliation:
Clínica Psiquiátrica “A” de la Universidad Aristóteles de Tesa Iónica, Hospital Psiquiátrico de Tesa Iónica, Tesalónica, Grecia
A. Balla
Affiliation:
Clínica Psiquiátrica “A” de la Universidad Aristóteles de Tesa Iónica, Hospital Psiquiátrico de Tesa Iónica, Tesalónica, Grecia
A. Karavatos
Affiliation:
Clínica Psiquiátrica “A” de la Universidad Aristóteles de Tesa Iónica, Hospital Psiquiátrico de Tesa Iónica, Tesalónica, Grecia
Get access

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Informe clínico
Information
European Psychiatry (Ed. Española) , Volume 8 , Issue 5 , June 2001 , pp. 330 - 331
Copyright
Copyright © European Psychiatric Association 2001

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bibliografía

Cabrera, Gómez JA, Cordero, Gutiérrez JR, Fernandez, López O, Reyes, Gutiérrez B, Romero, García K, Simón, Conuegra Jet al. Treatment of schizophrenic disorder, paranoid type, with intramuscular recombinant alpha-2b interferon. Biotherapy 1993; 7: 27–37.Google Scholar
Danzer, R, Wollman, E, Vitkovic, L, Yirmiya, RCytokines and depression: fortuitous or causative association? Mol Psychiatry 1999; 4: 328–32.CrossRefGoogle Scholar
Hadden, JWImmunopharmacology of cáncer, infection and autoimmunity. Fundam Clin Pharmacol 1987; 4: 283–96.CrossRefGoogle Scholar
Katila, H, Cantell, C, Appelberg, B, WablLeck, K, Naukkarinen, H, Rimon, RInterferon-alpha as adjuvant treatment in chronic schizophrenia. Neuropsychobiology 1993; 28: 192–6.CrossRefGoogle ScholarPubMed
Lemounier, E, Condal, B, Paillere-Martinot, ML, Chollet, R, Allilaire, JFSyndrome de perseceution sous interferon: á propose d'un cas. Ann Med Psychol 1996; 154: 246–8.Google Scholar
Lerner, DM, Stoudemire, A, Rosenstein, DLNeuropsychiatric toxocity associated with cytokine therapies. Psychosomatics 1999; 40: 428–35.CrossRefGoogle Scholar
Licinio, L, Kling, MA, Hauser, PCytolines and brain function: relevance to interferon-alpha-induced mood and cognitive changes. Semin Oncol 1998; 25 (Suppl 1): 30–8.Google Scholar
Monji, A, Yoshida, L, Tashiro, Kl, Hayashi, Y, Tashiro, NA case of persisten manic depressive illness induced by interferonalpha in the treatment of chronic hepatitis C. Psychosomatics 1998; 39: 562–4.CrossRefGoogle Scholar
Okada, FInterferon-induced depression: just one of Bonhoefer's exogene reactiontypen or a clue to understanding psychoimmunological aspects of depression? J Mol Med 1995; 73: 99–100.CrossRefGoogle ScholarPubMed
Shiffman, MLThe use of high-dose interferon in the treatment of chronic hepatitis C. Semin Liver Dis 1999; 19 (Suppl 1): 25–34.Google ScholarPubMed
Vial, T, Choquet-Kastylevsky, G, Liautard, C, Descotes, JEndocrine and neurological adversa effects of therapeutic interferons. Toxicology 2000; 142: 161–72.CrossRefGoogle Scholar